Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Sharad, Ghamande"'
Autor:
David P. Mysona, Sharad Purohit, Katherine P. Richardson, Jessa Suhner, Bogna Brzezinska, Bunja Rungruang, Diane Hopkins, Gregory Bearden, Robert Higgins, Marian Johnson, Khaled Bin Satter, Richard McIndoe, Sharad Ghamande
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract In ovarian cancer, there is no current method to accurately predict recurrence after a complete response to chemotherapy. Here, we develop a machine learning risk score using serum proteomics for the prediction of early recurrence of ovarian
Externí odkaz:
https://doaj.org/article/0f7e4131e46541d290beb8521310bfc3
Autor:
Lucy Gilbert, Ana Oaknin, Prafull Ghatage, Rebecca Kristeleit, Wei Guo, Sharad Ghamande, Valentina Boni, Jubilee Brown, Xinwei Han, Vanessa Samouëlian, Ellie Im, Renaud Sabatier, Anna V Tinker, David M O’malley, Bhavana Pothuri, Cara Mathews, Jennifer Veneris, Tao Duan, Linda Duska, Joshua Press, Charles Leath III, Sybil Zildjian
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/e14cae0105ca4a77863badc972ff7d01
Autor:
David, Mysona, Katherine, Dorr, Alex, Ward, Ellen, Shaver, Bunja, Rungruang, Sharad, Ghamande
Publikováno v:
Gynecologic Oncology. 168:114-118
This study investigated whether there are pharmacogenomic markers predictive of chemotherapy induced peripheral neuropathy (CIPN) as a result of taxane-based chemotherapy.Patients were enrolled from August 2020 to November 2020 in a prospective, case
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9415af3a4652da961edaaa65869f8497
https://doi.org/10.1016/j.ygyno.2022.10.021
https://doi.org/10.1016/j.ygyno.2022.10.021
Autor:
Xiaolin Yu, Sharad Ghamande, Haitao Liu, Lu Xue, Shuhua Zhao, Wenxi Tan, Lijing Zhao, Shou-Ching Tang, Daqing Wu, Hasan Korkaya, Nita J. Maihle, Hong Yan Liu
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 10, Iss , Pp 317-330 (2018)
HER family members are interdependent and functionally compensatory. Simultaneously targeting EGFR/HER2/HER3 by antibody combinations has demonstrated superior treatment efficacy over targeting one HER receptor. However, antibody combinations have th
Externí odkaz:
https://doaj.org/article/59b967c81b704f36b46f263e8b73b15d
Multiplex glycan bead array for high throughput and high content analyses of glycan binding proteins
Autor:
Sharad Purohit, Tiehai Li, Wanyi Guan, Xuezheng Song, Jing Song, Yanna Tian, Lei Li, Ashok Sharma, Boying Dun, David Mysona, Sharad Ghamande, Bunja Rungruang, Richard D. Cummings, Peng George Wang, Jin-Xiong She
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-12 (2018)
The low throughput or content of current methods for the analysis of glycans-glycan binding proteins (GBPs) interactions hampers their clinical applications. Here, the authors conjugate synthesized glycans to Luminex beads to detect GBPs and apply it
Externí odkaz:
https://doaj.org/article/54bd91a6bdc84bbaaee3bb8a242ecc34
Autor:
Anthony, Bui, Paola A, Gehrig, Sharad, Ghamande, Bunja J, Rungruang, John K, Chan, David P, Mysona
Publikováno v:
Gynecologic Oncology. 167:205-212
To determine the utility of a clinical calculator to redefine prognosis and need for chemotherapy among patients with early-stage high-risk epithelial ovarian cancer.Data were abstracted for stage I-II, high-risk ovarian cancer from the National Canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5418af2f62bfeca0003db9db73280ed4
https://doi.org/10.1016/j.ygyno.2022.08.012
https://doi.org/10.1016/j.ygyno.2022.08.012
Autor:
Jung-Min Lee, Richard G. Moore, Sharad Ghamande, Min S. Park, John P. Diaz, Julia Chapman, James Kendrick, Brian M. Slomovitz, Krishnansu S. Tewari, Elizabeth S. Lowe, Tsveta Milenkova, Sanjeev Kumar, Mike Dymond, Jessica Brown, Joyce F. Liu
Publikováno v:
Clinical Cancer Research. 28:4186-4193
Purpose: The efficacy, safety, and tolerability of cediranib plus olaparib (cedi/ola) were investigated in patients with nongermline–BRCA-mutated (non-gBRCAm) platinum-resistant recurrent ovarian cancer. Patients and Methods: PARP inhibitor–naïv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41520f3c01be57479cfe72acb16a6a20
https://doi.org/10.1158/1078-0432.ccr-21-1733
https://doi.org/10.1158/1078-0432.ccr-21-1733
Autor:
Oliver Dorigo, Amit M. Oza, Tanja Pejovic, Prafull Ghatage, Sharad Ghamande, Diane Provencher, Lisa D. MacDonald, Heather Torrey, Valarmathy Kaliaperumal, Walead Ebrahimizadeh, Heather A. Hirsch, Yogesh Bramhecha, Jeannine Villella, Stephan Fiset
Publikováno v:
Clinical Cancer Research.
Purpose: Patients with platinum resistant ovarian cancer (OvCa) respond poorly to existing therapies. Hence there is a need for more effective treatments. Methods: The DeCidE1 trial is a multicenter, randomized, open-label, single-arm phase 2 study t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1f582f518dde062370107ff4852b658
https://doi.org/10.1158/1078-0432.ccr-22-2595
https://doi.org/10.1158/1078-0432.ccr-22-2595
Autor:
Daniela Matei, Mohammad Azab, Harold Keer, Yong Hao, Sue Naim, Aram Oganesian, Simone Jueliger, Kenneth P. Nephew, Geoff D. Hall, Patricia Braly, Benjamin Schwartz, Deborah K. Armstrong, Rebecca Kristeleit, Bristi Basu, Diane M. Provencher, Hal W. Hirte, Merry Jennifer Markham, Gini F. Fleming, Michael J. Birrer, Sharad Ghamande, William P. McGuire, Susana Banerjee, Sarah P. Blagden, Lynda D. Roman, John Nemunaitis, Angeles Alvarez Secord, Ursula A. Matulonis, Amit M. Oza
Purpose:Platinum resistance in ovarian cancer is associated with epigenetic modifications. Hypomethylating agents (HMA) have been studied as carboplatin resensitizing agents in ovarian cancer. This randomized phase II trial compared guadecitabine, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b59cc7356214d108dbd0dcf2c13ec6d9
https://doi.org/10.1158/1078-0432.c.6528422.v1
https://doi.org/10.1158/1078-0432.c.6528422.v1
Autor:
Gini F. Fleming, Mohammad Azab, Harold Keer, Xiang Yao Su, Sue Naim, Aram Oganesian, Simone Jueliger, Kenneth P. Nephew, Merry Jennifer Markham, John Nemunaitis, Angeles Alvarez Secord, Lynda Roman, Sharad Ghamande, Daniela Matei
Table S1. Efficacy Table S2. Descriptive Statistics of Guadecitabine Plasma Pharmacokinetic Parameters Table S3. Descriptive Statistics of Decitabine Plasma Pharmacokinetic Parameters Table S4. Genes Tested for Methylation and Expression Analysis of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dbd7e0d3c48c4045764772b803243ab
https://doi.org/10.1158/1078-0432.22463961.v1
https://doi.org/10.1158/1078-0432.22463961.v1